News Results for Shield Therapeutics (STX)

Iron deficiency focused Shield Therapeutics said it expected to post a fall in revenue that was nevertheless in line with market expectations. Revenue for the year through December was seen...

Pharmaceutical company Shield Therapeutics has secured a licence agreement in China for its lead product Feraccru/Accrufer. The deal is an exclusive licence agreement with Beijing Aosaikang...

Shield Therapeutics said it would present positive study results for its iron deficiency treatment at in Hamburg on Tuesday. The presentation would be held as part of United European...

James Karis, Chairman, bought 75,000 shares in the company on the 13th August 2019 at a price of 178.00p. The Director now holds 161,667 shares representing 0.00% of the shares in issue. Story...

Iron deficiency focused Shield Therapeutics booked a narrower first-half loss, as its grew sales and lowered spending on research and development. Pre-tax losses for the six months through June...

Peel Hunt today reaffirms its buy investment rating on Shield Therapeutics Plc (LON:STX) and raised its price target to 200p (from 88p). Story provided by StockMarketWire.com Broker Forecasts...

Pharmaceutical company Shield Therapeutics said it had received FDA approval in the United States for its Feraccru (Accrufer in the US) drug for the treatment of iron deficiency in adults. The...

UK stocks opened substantially lower on Monday after oil and mining stocks were hurt by growing fears about the health of US trade relationships with China and Mexico. At 0848, the FTSE 100 was...

Iron deficiency focused Shield Therapeutics said that Teva Pharmaceutical Industries had filed a notice of appeal regarding a previous patent ruling. Teva had filed a notice of appeal to the...

finnCap today initiates coverage of Shield Therapeutics Plc (LON:STX) with a corporate investment rating and price target of 200p. Story provided by StockMarketWire.com Broker Forecasts data...

Shield Therapeutics said Swiss regulators had extended the approved indication for its iron deficiency treatment to now include treatment of all adults with iron deficiency with or without...

Carl Sterritt, Chief Executive Officer, exercised 123,690 shares in the company on the 16th April 2019 at a price of 1.50p. The Director now holds 10,198,951 shares. Story provided by...

Peel Hunt today reaffirms its buy investment rating on Shield Therapeutics Plc (LON:STX) and raised its price target to 88p (from 70p). Story provided by StockMarketWire.com Broker Forecasts data...

Shield Therapeutics said it had recorded positive results from a clinical trial of its iron replacement therapy Feraccru. The AEGIS-H2H clinical trial compared Feraccru to Ferinject, or FCM, the...

Liberum Capital today reaffirms its buy investment rating on Shield Therapeutics Plc (LON:STX) and raised its price target to 116p (from 80p). Story provided by StockMarketWire.com Broker...

Shield Therapeutics reported positive results from a further study of a treatment for iron deficiency in adults with inflammatory bowel disease. The open-label extension phase of the study of...

Iron deficiency focused Shield Therapeutics said it had appointed James Karis as its new chairman with immediate effect. Karis had served on the company's board for almost three years and had...

Shield Therapeutics said that European distribution partner Norgine had launched its iron deficiency treatment in the UK. Sheild in September licensed the so-called Feraccru treatment to Norgine...

Shield Therapeutics said the US Food and Drug Administration had accepted for review a new drug application for its lead iron deficiency product. The regulator would shortly confirm to Shield the...

Shield Therapeutics said it received confirmation from the US Federal Drug Administration of a successful submission of a new drug application for iron deficiency treatment Feraccru. The product...

Carl Sterritt, Chief Executive Officer, bought 88,235 shares in the company on the 21st September 2018 at a price of 34.00p. The Director now holds 10,163,496 shares. Story provided by...

Peel Hunt today reaffirms its buy investment rating on Shield Therapeutics Plc (LON:STX) and set its price target at 70p. Story provided by StockMarketWire.com Broker Forecasts data provided by...

Liberum Capital today reaffirms its buy investment rating on Shield Therapeutics Plc (LON:STX) and set its price target at 80p. Story provided by StockMarketWire.com Broker Forecasts data...

Shield Therapeutics posted a first-half loss as it continued to invest in bringing its iron deficiency treatments towards commercialisation. The company also announced that it had entered into an...

Shield Therapeutics said its revenue in the first half was expected to reach £0.5m, following increased sales of its Feraccru iron deficiency treatment in Europe. The company's shares plunged in...

Shield Therapeutics said Andrew Heath would stand down as chairman to focus on other business interests. A process to appoint a successor to Heath, who became chairman in early 2016, was underway,...

Shield Therapeutics said annual losses deepened and that it would cut jobs and promotional spending to conserve cash, amid headwinds proving up the effectiveness of its Feraccru iron deficiency...

UK stocks opened lower on Friday as persistent trade-war fears continued to unsettle global markets. At 0856, the benchmark FTSE 100 index was down 15.23 points, or 0.2%, at 7.184,27 on what was a...

Shield Therapeutics said minutes from a US Food and Drug Administration meeting regarding its iron deficiency treatment Feraccru indicated it could re-submit a new drug application without...

Shield Therapeutics said the European Commission had decided to extend the approved indication for its Feraccru product to include treatment of all adults with iron deficiency, with or without...

Shield Therapeutics said it altered the results of a clinical study on a treatment for iron deficiency in a fashion that may, or may not, be accepted by the US Federal Drug Administration. A small...

Shield Therapeutics said European regulators had recommended marketing authorisation approval of its Feraccru treatment be extended to include all adults with iron deficiency, with or without...

Shield Therapeutics, a commercial stage, pharmaceutical company, is cutting costs ahead of a decision on the future of Feraccru - its lead asset which is approved and marketed in Europe for the...

The UK and Europe were in the red as concerns over potential rises in interest rates this year soured the market. The FTSE 100 was 1.4% lower at 7,334. However fears of a more significant...

The global sell-off continued in the US last week and Asia today on the back of rising government bond yields and an expected hike in interest rates. The negative sentiment spread to the UK's FTSE...

Shield Therapeutics said a clinical trial of its Feraccru treatment for anemia failed to meet the study's primary objectives. 'We are surprised and disappointed by these top-line findings,' chief...

Shield Therapeutics said it has finished enrolling subjects for the Phase 3 AEGIS-CKD study of its European-marketed product, Feraccru. Top-line data, based on a 16-week primary endpoint, is...

Carl Sterritt, Chief Executive Officer, bought 8,814 shares in the company on the 4th October 2017 at a price of 100.00p. The Director now holds 10,075,261 shares. NOTE: Call option Story...

finnCap today reaffirms its buy investment rating on Shield Therapeutics Plc (LON:STX) and cut its price target to 265p (from 270p). Story provided by StockMarketWire.com

finnCap today initiates coverage of Shield Therapeutics Plc (LON:STX) with a buy investment rating and price target of 270p. Story provided by StockMarketWire.com

Shield Therapeutics announced that the United States Patent and Trademark Office (USPTO) allowed a composition of matter patent protecting the active substance of Feraccru, the group's lead...

Shield Therapeutics has announced that the Company has raised approximately £12m (before expenses) through: - a co-ordinated exercise of 6,870,536 existing warrants at an exercise price of 150p...

Shield Therapeutics plans to raise a total of about £12m gross at 150p a share. This would be achieved via a warrant exercise to raise about 10.3m, a placing to raise about £1.5m and a subscription...

Liberum Capital today reaffirms its buy investment rating on Shield Therapeutics Plc (LON:STX) and cut its price target to 245p (from 310p). Story provided by StockMarketWire.com

Story provided by StockMarketWire.com

Story provided by StockMarketWire.com

Shield Therapeutics reported that pricing and reimbursement (P&R) agreements were slower than expected for its oral iron product Feraccru, although these approvals are now coming through. The...

Canaccord Genuity today reaffirms its buy investment rating on Shield Therapeutics Plc (LON:STX) and raised its price target to 241p (from 235p). Story provided by StockMarketWire.com

Shield Therapeutics, a speciality pharmaceutical company focused on secondary care, will report its results for the six months ended 30 June on 20 September. At 4:24pm: (LON:STX) Shield...

Canaccord Genuity today initiates coverage of Shield Therapeutics Plc (LON:STX) with a buy investment rating and price target of 235p. Story provided by StockMarketWire.com

Story provided by StockMarketWire.com

Shield Therapeutics has changed its accounting reference date from 30 September to 31 December and will publish its results for the year to the end of December 2015 on 14 June. At 1:18pm:...

Shield Therapeutics, a speciality pharmaceutical company focused on secondary care, started trading on AIM today with a market capitalisation of approximately GBP162 million. At 1:29pm:...

Shield Therapeutics said the European Commission has granted marketing authorisation across all member states for its wholly owned product, Feraccru, as a treatment for adults with iron deficiency...

Story provided by StockMarketWire.com